Savita Rangarajan

Publications

90 publications

Page 3 of 9

Multiyear follow-up of AAV5-hFVIII-SQ gene therapy for Hemophilia A

K. John Pasi, Savita Rangarajan, Nina Mitchell, Will Lester, Emily Symington, Bella Madan, Michael Laffan, Chris B. Russell, Mingjin Li, Glenn F. Pierce & Wing Y. Wong, 2020, New England Journal of Medicine, 382(1), 29-40

DOI: 10.1056/NEJMoa1908490

Type: article

Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A

Sophia Stanford, Ruth Pink, Desmond Creagh, Amanda Clark, Gillian Lowe, Nicola Curry, John Pasi, David Perry, Sylvia Fong, Gregory Hayes, Kandiah Chandrakumaran & Savita Rangarajan, 2019, Research and Practice in Thrombosis and Haemostasis, 3(2), 261-267

DOI: 10.1002/rth2.12177

Type: article

Rapid and sustained immune tolerance to inhibitors induced by a plasma‐derived, VWF‐containing FVIII concentrate

Elena Santagostino, Savita Rangarajan, Johannes Oldenburg, Roser Peiró‐jordan & Víctor Jiménez‐yuste, 2019, Haemophilia, 25(2)

DOI: 10.1111/hae.13676

Type: letterEditorial

Real life experiences of a PK dosing study-Challenges and lessons learned.

S. Mangles, C. Rea, B. Madan, E. I. Nielsen, S. Jönsson, J. Needham, P. W. Collins & S. Rangarajan, 2018, Haemophilia, 24(3), e145-e148

DOI: 10.1111/hae.13470

Type: letterEditorial

Pharmacokinetics, clot strength and safety of a new fibrinogen concentrate: randomized comparison with active control in congenital fibrinogen deficiency

C. Ross, S. Rangarajan, M. Karimi, G. Toogeh, S. Apte, T. Lissitchkov, S. Acharya, M. J. Manco-johnson, A. Srivastava, B. Brand, B. A. Schwartz, S. Knaub & F. Peyvandi, 2018, Journal of Thrombosis and Haemostasis, 16(2), 253-261

DOI: 10.1111/jth.13923

Type: article

Efficacy and safety of Nuwiq® (human-cl rhFVIII) in patients with severe haemophilia A undergoing surgical procedures

N. Zozulya, C. M. Kessler, A. Klukowska, M. Von Depka, K. Hampton, C. R. M. Hay, M. Jansen, J. Bichler, S. Knaub & S. Rangarajan, 2018, Haemophilia, 24(1), 70-76

DOI: 10.1111/hae.13351

Type: article

AAV5–Factor VIII gene transfer in severe hemophilia A

Savita Rangarajan, Liron Walsh, Will Lester, David Perry, Bella Madan, Michael Laffan, Hua Yu, Christian Vettermann, Glenn F. Pierce, Wing Y. Wong & K. John Pasi, 2017, New England Journal of Medicine, 377(26), 2519-2530

DOI: 10.1056/NEJMoa1708483

Type: article

The evolving role and future relevance of plasma-derived therapies in the management of bleeding disorders

Víctor Jiménez-Yuste, Rebecca Kruse-Jarres, Savita Rangarajan & Carme Altisent, 2017, Thrombosis and Haemostasis, 116(S 01), S1

DOI: 10.1160/TH16-01-0047

Type: article

Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates

Alfonso Iorio, Kathelijn Fischer, Victor Blanchette, Savita Rangarajan, Guy Young & Massimo Morfini, 2017, Thrombosis and Haemostasis, 117(06), 1023-1030

DOI: 10.1160/TH16-12-0942

Type: article

First-line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties

P. Collins, E. Chalmers, J. Alamelu, C. Hay, R. Liesner, M. Makris, M. Mathias, J. Payne, S. Rangarajan, M. Richards, K. Talks, O. Tunstall, M. Williams & D. P. Hart, 2017, Haemophilia, 23(5), 654-659

DOI: 10.1111/hae.13264

Type: article

Professor Savita Rangarajan

Connect with Savita

Publications